At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 32 enrolled
Drug / intervention
MT203 80 mg or matching Placebo +2 moredrug
Likely dose
MT203 80 mg or matching Placebofrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Single-center, Double-Blind, Placebo-Controlled Phase 1 Study to Evaluate Safety and Pharmacokinetics of Single Subcutaneous Injection of MT203 in Healthy Adult Japanese and Caucasian Male Participants
In Brief
A Phase 1 clinical trial evaluating MT203 80 mg or matching Placebo, MT203 150mg or matching Placebo, and 1 other intervention for Healthy Volunteers. Completed, enrolled 32 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate safety, pharmacokinetics and pharmacodynamics of single subcutaneous injection of MT203 in healthy adult Japanese and Caucasian male participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesJapan
Collaborators--
Timeline
Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartNov 2014
First PostedFeb 2015
Primary CompletionMay 2015
TodayJul 2026
First PostedFeb 3, 2015
Enrollment StartNov 1, 2014
Primary CompletionMay 1, 2015
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 11.4 years ago
Interventions
MT203 80 mg or matching Placebodrug
MT203 80 mg or matching placebo injection
MT203 150mg or matching Placebodrug
MT203 150mg or matching placebo injection
MT203 300 mg or matching placebodrug
MT203 300 mg or matching placebo injection